open access

Vol 14, No 5 (2019)
Editorial
Get Citation

Editorial

Beata Wożakowska-Kapłon
DOI: 10.5603/FC.2019.0108
·
Folia Cardiologica 2019;14(5).

open access

Vol 14, No 5 (2019)
Editorial

Abstract

Not available

Abstract

Not available
Get Citation
About this article
Title

Editorial

Journal

Folia Cardiologica

Issue

Vol 14, No 5 (2019)

DOI

10.5603/FC.2019.0108

Bibliographic record

Folia Cardiologica 2019;14(5).

Authors

Beata Wożakowska-Kapłon

References (10)
  1. EMA.pr.2018.08.10: EMA. Update on review of valsartan medicines due to detection of NDMA: EMA reviewing valsartan produced by another company Zhejiang Tianyu. Press release, document EMA/543774/2018, 10 August 2018. https://www.ema.europa.eu/en/documents/press-release/update-review-valsartan-medicines-due-detection-ndma_en.pdf (2019.07.30).
  2. EDQM.pr.2018.08.28: EDQM: Update on EDQM’s actions following detection of impurity in valsartan. Press release. 28 August 2018, Strasbourg, France. ttps://www.edqm.eu/sites/default/files/pressrelease-update-on-edqm-actions-following-detection-of-impurity-in-valsartan-august2018.pdf (2019.07.30).
  3. FDA.up.2018.12.20: 12/20/2019: UPDATE — FDA alerts patients and health care professionals to Torrent’s recall of losartan medication due to NDEA. https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-and-press-announcements-angiotensin-ii-receptor-blocker-arb-recalls-valsartan-losartan (2019.07.30).
  4. EMA.pr.2018.09.13: EMA. Update on review of valsartan medicines: risk from NDMA remains low, a related substance NDEA also being investigated. Press release 13/09/2018, document EMA/585263/2018. https://www.ema.europa.eu/en/documents/press-release/update-review-valsartan-medicines_en.pdf (2019.07.30).
  5. FDA.fnr.2018.09.13: FDA provides update on its ongoing investigation into valsartan products; and reports on the finding of an additional impurity identified in one firm’s already recalled products. FDA news release. https://www.fda.gov/news-events/press-announcements/fda-provides-update-its-ongoing-investigation-valsartan-products-and-reports-finding-additional (2019.07.30).
  6. EMA.pr.2018.11.19: EMA. Valsartan from Mylan laboratories in India can no longer be used in EU medicines due to NDEA impurity. Press release 19/11/2018, document EMA/809509/2018. URL: https://www.ema.europa.eu/en/documents/press-release/valsartan-mylan-laboratories-india-can-no-longer-be-used-eu-medicines-due-ndea-impurity_en.pdf (dostęp 2019.07.30). https://www.ema.europa.eu/en/documents/press-release/valsartan-mylan-laboratories-india-can-no-longer-be-used-eu-medicines-due-ndea-impurity_en.pdf (2019.07.30).
  7. EDQM.up.CEP2018.11.19: EDQM: Update on the review of CEP applications for sartans, 2018.11.19. Strasbourg, France. https://www.edqm.eu/en/news/update-review-cep-applications-sartans (2019.07.13).
  8. FDA.up.2018.11.21: 11/21/2018: UPDATE — FDA alerts patients and health care professionals to Mylan’s recall of valsartan products due to NDEA. https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-and-press-announcements-angiotensin-ii-receptor-blocker-arb-recalls-valsartan-losartan (2019.07.30).
  9. RIS.up.2018.12.24: Europe Update on the review of CEP applications for sartans. Par RIS.WORLD — 24/12/2018. http://www.ris.world/europe-update-on-the-review-of-cep-applications-for-sartans-2/ (2019.07.16).
  10. FDA.up.2019.01.02: 1/2/2019: UPDATE — FDA alerts patients and health care professionals to Aurobindo’s recall of valsartan medication due to NDEA. https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-and-press-announcements-angiotensin-ii-receptor-blocker-arb-recalls-valsartan-losartan (2019.07.30).

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl